H.R. 1082
Sets penalties for mishandling cell and tissue products
Adds fines for breaking federal rules on donor eligibility and handling of human cell and tissue products, and requires the FDA to educate providers and report to Congress.
- Fines apply to violations of rules on donor eligibility and good tissue practices
- FDA must hold workshops and open a public comment period on these products
- FDA must report to Congress with recommendations
- FDA must post online information about its Tissue Reference Group and related inspections
Passed the House · Senate's turn